Related Experiment Video
Updated: Oct 23, 2025
Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
Published on: May 30, 2016
Current status of developing tissue engineering vascular technologies
Ryuma Iwaki1, Toshihiro Shoji1, Yuichi Matsuzaki1
1Center for Regenerative Medicine, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Insights
Tissue engineering offers promising alternatives to artificial materials for cardiovascular disease (CVD) treatment. These innovative approaches may improve surgical outcomes and eliminate the need for repeat interventions, especially in pediatric patients.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Cardiovascular Surgery
Background:
- Cardiovascular disease (CVD) remains a primary cause of mortality in Western nations.
- While surgical interventions for CVD are advancing, the use of artificial prosthetic materials presents significant postoperative challenges and limitations, particularly in pediatric patients due to their lack of growth potential.
- These limitations necessitate future re-interventions, highlighting the need for improved treatment strategies.
Purpose of the Study:
- To review current tissue-engineering (TE) technologies for treating cardiovascular diseases.
- To discuss the limitations of existing TE approaches based on evidence from animal studies and clinical trials.
Main Methods:
- Comprehensive literature review of tissue-engineering technologies for cardiovascular applications.
- Analysis of data from preclinical animal studies and clinical trials.
Main Results:
- Tissue-engineered constructs, utilizing autologous cells and biodegradable scaffolds, demonstrate potential for mechanical function comparable to native tissue.
- These constructs offer theoretical advantages in biocompatibility and possess inherent growth potential, potentially avoiding repeat interventions associated with prosthetic materials.
Conclusions:
- Tissue engineering holds significant promise for improving cardiovascular surgical outcomes and patient care.
- Despite ongoing research and development, most current TE technologies are not yet ready for widespread clinical application.
- Further advancements are crucial to translate the potential of tissue engineering into effective clinical treatments for cardiovascular diseases.
Introduction:
Cardiovascular disease (CVD) is the leading cause of death in western countries. Although surgical outcomes for CVD are dramatically improving with the development of surgical techniques, medications, and perioperative management strategies, adverse postoperative events related to the use of artificial prosthetic materials are still problematic. Moreover, in pediatric patients, using these artificial materials make future re-intervention inevitable due to their lack of growth potential.
Areas Covered:
This review focuses on the most current tissue-engineering (TE) technologies to treat cardiovascular diseases and discusses their limitations through reports ranging from animal studies to clinical trials.
Expert Opinion:
Tissue-engineered structures, derived from a patient's own autologous cells/tissues and biodegradable polymer scaffolds, can provide mechanical function similar to non-diseased tissue. However, unlike prosthetic materials, tissue-engineered structures are hypothetically more biocompatible and provide growth potential, saving patients from additional or repetitive interventions. While there are many methods being investigated to develop TE technologies in the hopes of finding better options to tackle CVD, most of these approaches are not ready for clinical use or trials. However, tissue engineering has great promise to potentially provide better treatment options to vastly improve cardiovascular surgical outcomes.
